EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zenith Healthcare's EBITDA for the
three
months ended in Mar. 2026 was ₹-3.6 Mil. Zenith Healthcare's Revenue for the
three
months ended in Mar. 2026 was ₹26.2 Mil. Therefore, Zenith Healthcare's EBITDA margin for the quarter that ended in Mar. 2026 was -13.66%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zenith Healthcare EBITDA Margin % Related Terms
Zenith Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zenith Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530665 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Healthcare EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zenith Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Healthcare (BOM:530665) has a EBITDA Margin % of -13.66% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zenith Healthcare and its competitors. Over the past decade, Zenith Healthcare's EBITDA Margin % has ranged from 2.69 to 7.12. According to the industry distribution chart, Zenith Healthcare ranks #693 out of 953 companies in the Drug Manufacturers industry, placing it in the top 72.7%.
Is Zenith Healthcare's EBITDA Margin % too high?
Zenith Healthcare's current EBITDA Margin % is -13.66%. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 7.12. Based on the distribution chart, Zenith Healthcare ranks #693 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zenith Healthcare has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenith Healthcare's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zenith Healthcare ranks #693 out of 953 companies for EBITDA Margin %. This places Zenith Healthcare in the lower half of its industry. The industry median EBITDA Margin % is 12.54. Historically, Zenith Healthcare's own EBITDA Margin % has ranged from 2.69 to 7.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zenith Healthcare and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Healthcare's current EBITDA Margin % is -13.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Zenith Healthcare (BOM:530665) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹3.65, compared to a current price of ₹3.04 — trading 16.7% below its estimated fair value. The current EBITDA Margin % is -13.66%. Zenith Healthcare's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zenith Healthcare (BOM:530665), the current EBITDA Margin % is -13.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenith Healthcare (BOM:530665) Overvalued in 2026?
Based on GuruFocus' analysis, Zenith Healthcare stock appears to be undervalued.
The current stock price of ₹3.04 is trading 16.7% below its estimated GF Value™ of ₹3.65.
GuruFocus considers Zenith Healthcare to be Modestly Undervalued.
Key valuation signals for BOM:530665:
EBITDA Margin %: -13.66%
GF Value™: ₹3.65 vs. price of ₹3.04 (16.7% below fair value)
No single metric tells the full story. See the BOM:530665 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenith Healthcare Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and trading of pharmaceutical formulations. The company also undertakes contracts for manufacturing business. It manufactures pharmaceutical formulations in the form of Tablets, Capsules, Oral liquids, and injectables. The company sells its products in India and also exports internationally.
66GF Score
Get the complete analysis for BOM:530665
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530665 has been successfully added to your 
